Journal Mobile Options
Table of Contents
Vol. 27, No. 1, 2004
Issue release date: February 2004
Add to my selection Citation Download
Onkologie 2004;27:83–90
(DOI:10.1159/000075611)
Review Article · Übersichtsarbeit

Tumour Hypoxia: Impact on Biology, Prognosis and Treatment of Solid Malignant Tumours

Weinmann M.a · Belka C.a · Plasswilm L.b
aKlinik für Radioonkologie, Universität Tübingen, Germany; bRadioonkologie, Universitätsklinik, Kantonsspital Basel, Switzerland Onkologie 2004;27:83–90 (DOI:10.1159/000075611)

Abstract

Tumour hypoxia is a major constraint for radiotherapy and many types of chemotherapy. A variety of different pathogenetic mechanisms contribute to the development of hypoxia in solid tumours. Hypoxia is associated with unfavourable prognosis, regardless of the treatment modality applied. Two different effects have been considered to explain the deleterious effects of hypoxia on the outcome of tumour patients. The first aspect encompasses the direct interference of hypoxia with antineoplastic treatment modalities. The efficacy of ionizing radiation, but also of a variety of cytotoxic drugs and cytokines rely directly on adequate oxygen tensions. The second aspect concerns the effects of hypoxia on the biology of tumour and stromal cells. Hypoxia is related to malignant progression, increased invasion, angiogenesis and an increased risk of metastasis formation. Possibly, hypoxia is furthermore a stressor which selects cells with increased resistance to apoptosis and thereby indirectly contributes to treatment resistance. This article reviews in brief the specific pathophysiology of tumour oxygenation and its implications for prognosis, tumour treatment and biology.

 goto top of outline Publication Details

Onkologie (International Journal for Cancer Research and Treatment)
Offizielles Organ von DGHO – Deutsche Gesellschaft für Hämatologie und Onkologie / ÖGHO – Österreichische Gesellschaft für Hämatologie und Onkologie / DFaG – Deutsche Fatigue Gesellschaft / AIO – Arbeitsgemeinschaft Internistische Onkologie in der deutschen Krebsgesellschaft e.V.

Vol. 27, No. 1, Year 2004 (Cover Date: February 2004)

Journal Editor: H.-J. Schmoll, Halle
ISSN: 0378–584X (print), 1423–0240 (Online)

For additional information: http://www.karger.com/onk


Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.